PMID- 31641639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Electronic)
IS  - 2230-9500 (Linking)
VI  - 23
IP  - 3
DP  - 2019 May-Jun
TI  - Effect of Sertraline as an Add-on Therapy in T2DM Patients with Comorbid 
      Depression: An Open Label Randomized Controlled Trial.
PG  - 357-362
LID - 10.4103/ijem.IJEM_67_19 [doi]
AB  - OBJECTIVES: To study the effect of sertraline on depression in type 2 diabetes 
      mellitus (T2DM) patients with comorbid depression. MATERIALS AND METHODS: An open 
      label randomized control study. Patients with T2DM and moderate to severe 
      depression were randomized to sertraline or control therapy for six months. The 
      primary objective was the change in depression score and the secondary objectives 
      were changes in glycemic parameters, wellbeing, and drug adherence scores at 
      three and six months. RESULTS: The present study includes 160 T2DM patients with 
      moderate to severe depression. Depression in these patients was evaluated using a 
      self-reporting version of Patient Health Questionnaire (PHQ-9). A total of 80 
      patients each were randomized to sertraline and control groups. Sertraline 
      significantly improved depression scores in patients with T2DM and moderate to 
      severe depression both at 3 months and 6 months compared to the control group. 
      The wellbeing and treatment adherence scores improved significantly in the 
      sertraline group at 6 months. However, sertraline had no significant effect on 
      glycemic parameters when compared to control group both at 3 months and 6 months. 
      CONCLUSION: Sertraline significantly improves depression and drug adherence in 
      T2DM patients with depression but has no effect on glycemic parameters.
CI  - Copyright: (c) 2019 Indian Journal of Endocrinology and Metabolism.
FAU - Kumar, Padala R
AU  - Kumar PR
AD  - Department of Endocrinology, MKCG Medical College, Berhampur, Odisha, India.
FAU - Chatterjee, Anindita
AU  - Chatterjee A
AD  - Department of Pharmacology, MKCG Medical College, Berhampur, Odisha, India.
FAU - P Behera, Jayanti
AU  - P Behera J
AD  - Department of Endocrinology, MKCG Medical College, Berhampur, Odisha, India.
FAU - Patnaik, Sudhiranjan
AU  - Patnaik S
AD  - Department of Endocrinology, MKCG Medical College, Berhampur, Odisha, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC6683678
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - health wellbeing
OT  - major depression
OT  - medication adherence
COIS- There are no conflicts of interest.
EDAT- 2019/10/24 06:00
MHDA- 2019/10/24 06:01
PMCR- 2019/05/01
CRDT- 2019/10/24 06:00
PHST- 2019/10/24 06:00 [entrez]
PHST- 2019/10/24 06:00 [pubmed]
PHST- 2019/10/24 06:01 [medline]
PHST- 2019/05/01 00:00 [pmc-release]
AID - IJEM-23-357 [pii]
AID - 10.4103/ijem.IJEM_67_19 [doi]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2019 May-Jun;23(3):357-362. doi: 
      10.4103/ijem.IJEM_67_19.